Erdafitinib

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Erdafitinib
Erdafitinib.svg
Clinical data
SynonymsJNJ-42756493
Identifiers
CAS Number
PubChem CID
UNII
KEGG
ECHA InfoCard100.235.008 Edit this at Wikidata
Chemical and physical data
FormulaC25H30N6O2
Molar mass446.555 g·mol−1
3D model (JSmol)

Erdafitinib[1] is a small molecule inhibitor of FGFR approved for treatment of cancer and marketed under the name Balversa. FGFRs are a subset of tyrosine kinases which are unregulated in some tumors and influence tumor cell differentiation, proliferation, angiogenesis, and cell survival.[2] Astex Pharmaceuticals discovered the drug and licensed it to Janssen Pharmaceuticals for further development.

Researchers have investigated erdafitinib for safety and efficacy in treatment of cholangiocarcinoma, gastric cancer, non-small cell lung cancer, and esophageal cancer.[3]

In March 2018, erdafitinib was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for treatment of urothelial cancer.[2]

In April 2019, erdafitinib was granted approval by the FDA for treatment of metastatic or locally advanced bladder cancer with an FGFR3 or FGFR2 alteration that has progressed beyond traditional platinum-based therapies, subject to a confirmatory trial.[4]

References[edit]

  1. ^ https://searchusan.ama-assn.org/usan/documentDownload?uri=%2Funstructured%2Fbinary%2Fusan%2Ferdafitinib.pdf
  2. ^ a b "Janssen Announces U.S. FDA Breakthrough Therapy Designation for Erdafitinib in the Treatment of Metastatic Urothelial Cancer - Johnson & Johnson". www.jnj.com.
  3. ^ "Erdafitinib - Janssen Pharmaceutica - AdisInsight". adisinsight.springer.com.
  4. ^ "FDA approves first targeted therapy for metastatic bladder cancer". www.fda.gov. Retrieved 2019-05-13.